Polymorphisms of the LEP- and LEPR genes, metabolic profile after prolonged clozapine administration and response to the antidiabetic metformin

Schizophrenia Research

Volumn 121, Issue 1-3, 2010, Pages 213-217

  Fernández, Erika ^a   Carrizo, Edgardo ^a   Fernández, Virginia ^a   Connell, Lisette ^a   Sandia, Ignacio ^b   Prieto, Dexy ^a   Mogollón, Johana ^b   Valbuena, Dennys ^c   Fernández, Iliana ^c   de Baptista, Enma Araujo ^d   Baptista, Trino ^e  

^a UNIVERSIDAD DEL ZULIA   (Venezuela)

^b Hospital Universitario de Los Andes   (Venezuela)

^c CATESFAM   (Venezuela)

^d UNIVERSIDAD DE LOS ANDES   (Venezuela)

^e Universidad De Los Andes Facultad de Medicina   (Venezuela)

Author keywords

Antidiabetics; Atypical antipsychotics; Genotype; Leptin; Metabolic syndrome; Obesity; Receptors

Indexed keywords

CLOZAPINE; GLUCOSE; HEMOGLOBIN A1C; HYDROCORTISONE; LEPTIN; LEPTIN RECEPTOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENOTYPE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYDROCORTISONE BLOOD LEVEL; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; EPIDEMIOLOGY; GENETICS; INSULIN RESISTANCE; METABOLIC DISORDER; MIDDLE AGED; PATHOPHYSIOLOGY; PHARMACOGENETICS; VENEZUELA;

ADULT; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; BODY MASS INDEX; CLOZAPINE; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HUMANS; HYDROCORTISONE; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LEPTIN; MALE; METABOLIC DISEASES; METFORMIN; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, LEPTIN; SCHIZOPHRENIA; VENEZUELA;

EID: 77955058083     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.06.001     Document Type: Article

References (27)

1. Ausubel, F., Brent, R., Kingston, R., Moore, D., Seidman, J., Smith, J., Struh, l .K., 1989. Preparation of genomic DNA. Phenol extraction and concentration of DNA from aqueous solutions. In: Short protocols in Molecular Biology. Current protocols in Molecular Biology. Ed. Reene Publishing associates and Wiley-Interscience; New York. p.114.1-115.4.
2. Baptista T., Dávila A., ElFakih Y., Uzcátegui E., Rangel N., Olivares Y., Galeazzi T., Vargas D., Peña R., Marquina D., Villarroel V., Teneud L., Beaulieu S. Similar frequency of abnormal correlation between serum leptin levels and body mass index before and after olanzapine treatment in schizophrenia. Int. Clin. Psychopharmacol. 2007, 22(4):205-211.
3. Baptista T., Sandia I., LaCruz A., Rangel N., de Mendoza S., Beaulieu S., Contreras Q., Galeazzi T., Vargas D. Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin. Int. Clin. Psychopharmacol. 2007, 22(2):69-76.
4. Calarge C.A., Ellingrod V.L., Zimmerman B., Acion L., Sivitz W.I., Schlechte J.A. Leptin gene -2548G/A variants predict risperidone-associated weight gain in children and adolescents. Psychiatr. Genet. 2009, 19(6):320-327.
5. Carrizo E., Fernández V., Sandia I., Pirela D., Connel L., Valbuena D., Araujo de Baptista E., Baptista T. Extended release metfomin for metabolic control assistance during prolonged clozapine administration: a 14week, double-blind, parallel group, placebo-controlled study. Schiz Res. 2009, 113(1):16-26.
6. Carrizo E., Fernández V., Sandia I., Pirela D., Connel L., Valbuena D., Araujo de Baptista E., Baptista T. Corrigendum to: Extended release metfomin for metabolic control assistance during prolonged clozapine administration: a 14week, double-blind, parallel group, placebo-controlled study. Schiz. Res. 2009, 115(1):96.
7. Ellingrod V.L., Bishop J.R., Moline J., Lin Y.C., del Miller D. Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia. Psychopharmacol. Bul. 2007, 40:57-62.
8. Eriksson A., Attvall S., Bonnier M., Eriksson J.W., Rosander B., Karlsson F.A. Short-term effects of metformin in type 2 diabetes. Diab. Obes. Metab. 2007, 9(4):483-489.
9. Fruehwald-Schultes B., Oltmanns K.M., Toschek B., Sopke S., Kern W., Born J., Fehm H.L., Peters A. Short-term treatment with metformin decreases serum leptin concentration without affecting body weight and body fat content in normal-weight healthy men. Metabolism 2002, 51(4):531-536.
10. Gregoor J.G., van der Weide J., Mulder H., Cohen D., Egberts A.C., van Megen H.J., Heerdink E.R. Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication. J. Clin. Psychopharmacol. 2009, 29(1):21-25.
11. Haupt D.W., Luber A., Maeda J., Melson A.K., Schweiger J.A., Newcomer J.W. Plasma leptin and adiposity during antipsychotic treatment of schizophrenia. Neuropsychopharmacol. 2005, 30(1):184-191.
12. Kang S.G., Lee H.J., Park Y.M., Choi J.E., Han C., Kim Y.K., Kim S.H., Lee M.S., Joe S.H., Jung I.K., Kim L. Possible association between the -2548A/G polymorphism of the leptin gene and olanzapine-induced weight gain. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32(1):160-163.
13. Kim J.Y., Park Y.H., Park S.Y., Choi K.H., Won K.C., Huh J.Y., et al. Metformin restores leptin sensitivity in high-fat-fed obese rats with leptin resistance. Diabetes 2006, 55:716-724.
14. Klein J., Westphal S., Kraus D., Meier B., Perwitz N., Ott V., Fasshauer M., Klein H.H. Metformin inhibits leptin secretion via a mitogen-activated protein kinase signalling pathway in brown adipocytes. J. Endocrinol. 2004, 183(2):299-307.
15. Li L., Mamputu J.C., Wiernsperger N., Renier G. Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin: inhibitory effect of metformin. Diabetes 2005, 54:2227-2234.
16. Marciniak A., Nawrocka-Rutkowska J., Brodowska A., Sienkiewicz R., Szydlowska I., Starczewski A. Leptin concentrations in patients with polycystic ovary syndrome before and after metformin treatment depending on insulin resistance, body mass index and androgen concentrations-introductory report. Folia Histochem. Cytobiol. 2009, 47(2):323-328.
17. Melkersson K.I., Hulting A.L., Brismar K.E. Elevated levels of insulin, leptin and blood lipids in olanzapine-treated Patients with schizophrenia or related psychoses. J. Clin. Psychiatry 2000, 61(10):742-749.
18. Mick G.J., Wang X., Ling Fu C., McCormick K.L. Inhibition of leptin secretion by insulin and metformin in cultured rat adipose tissue. Biochim. Biophys. Acta 2000, 1502(3):426-432.
19. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extraction DNA from human nucleated cells. Nucleic Acids Res. 1988, 16(3):1215.
20. Mueller W.M., Stanhope K.L., Gregoire F., Evans J.L., Havel P.J. Effects of metformin and vanadium on leptin secretion from cultured rat adipocytes. Obes. Res. 2000, 8:530-539.
21. Peña R., Marquina D., Serrano A., ElFakih Y., Carrizo E., Fernandez V., Araujo de Baptista E., Teneud L., Baptista T. Frequency of abnormal correlation between leptin and the body mass index during first and second generation antipsychotic drug treatment. Schiz Res. 2008, 106(2-3):315-319.
22. Ryu S.H., Jang W.S., Cho E.Y., Kim S.K., Lee D.S., Hong K.S. Association study of -2548A/G polymorphism of leptin gene with antipsychotics-induced weight gain. Korean J Psychopharmacol. 2006, 17:423-438.
23. Sivitz W.I., Wayson S.M., Bayless M.L., Larson L.F., Sinkey C., Robert S. Leptin and body fat in type 2 diabetes and monodrug therapy. J. Clin. Endocrinol. Metab. 2003, 88:1543-1553.
24. Snoussi K., Strosberg A.D., Bouaouina N., Ahmed S.B., Helal A.N., Chouchane L. Leptin and leptin receptor polymorphisms are associated with increased risk and poor prognosis of breast carcinoma. BMC Cancer 2006, 6:38.
25. Templeman L.A., Reynolds G.P., Arranz B., San L. Polymorphisms of the 5-HT2Creceptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet. Genomics 2005, 15:195-200.
26. Zhang Z.J., Yao Z.J., Mou X.D., Chen J.F., Zhuk R.X., Liu W., Zhang X.R., Zung J., Hou G. Association of -2548G/A functional polymorphism in the promoter region of leptin gene with antipsychotic agent-induced weight gain. Zhonghua Yi Xue Za Zhi 2003, 83(24):2119-2123.
27. Zhang X.Y., Tan Y.L., Zhou D.F., Haile C.N., Cao L.Y., Xu Q., Shen Y., Kosten T.A., Kosten T.R. Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population. J. Clin. Psychopharmacol. 2007, 27(3):246-251.